|
1
|
Ostrom QT, Gittleman H, Farah P, Ondracek
A, Chen Y, Wolinsky Y, Stroup NE, Kruchko C and Barnholtz-Sloan JS:
CBTRUS statistical report: Primary brain and central nervous system
tumors diagnosed in the United States in 2006–2010. Neuro Oncol.
15:(Suppl 2). ii1–ii56. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lin Y, Shi R, Wang X and Shen HM:
Luteolin, a flavonoid with potentials for cancer prevention and
therapy. Curr Cancer Drug Targets. 8:634–646. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Moon YJ, Wang X and Morris ME: Dietary
flavonoids: Effects on xenobiotic and carcinogen metabolism.
Toxicol In Vitro. 20:187–210. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chian S, Thapa R, Chi Z, Wang XJ and Tang
X: Luteolin inhibits the Nrf2 signaling pathway and tumor growth in
vivo. Biochem Biophys Res Commun. 447:602–608. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chang J, Hsu Y, Kuo P, Kuo Y, Chiang L and
Lin C: Increase of Bax/Bcl-XL ratio and arrest of cell cycle by
luteolin in immortalized human hepatoma cell line. Life Sci.
76:1883–1893. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee HJ, Wang CJ, Kuo HC, Chou FP, Jean LF
and Tseng TH: Induction apoptosis of luteolin in human hepatoma
HepG2 cells involving mitochondria translocation of Bax/Bak and
activation of JNK. Toxicol Appl Pharmacol. 203:124–131. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lim DY, Jeong Y, Tyner AL and Park JH:
Induction of cell cycle arrest and apoptosis in HT-29 human colon
cancer cells by the dietary compound luteolin. Am J Physiol
Gastrointest Liver Physiol. 292:G66–G75. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tang X, Wang H, Fan L, Wu X, Xin A, Ren H
and Wang XJ: Luteolin inhibits Nrf2 leading to negative regulation
of the Nrf2/ARE pathway and sensitization of human lung carcinoma
A549 cells to therapeutic drugs. Free Radic Biol Med. 50:1599–1609.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Youdim KA, Qaiser MZ, Begley DJ,
Rice-Evans CA and Abbott NJ: Flavonoid permeability across an in
situ model of the blood-brain barrier. Free Radic Biol Med.
36:592–604. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jang S, Kelley KW and Johnson RW: Luteolin
reduces IL-6 production in microglia by inhibiting JNK
phosphorylation and activation of AP-1. Proc Natl Acad Sci USA.
105:7534–7539. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hendriks JJ, Alblas J, van der Pol SM, van
Tol EA, Dijkstra CD and de Vries HE: Flavonoids influence monocytic
GTPase activity and are protective in experimental allergic
encephalitis. J Exp Med. 200:1667–1672. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Etienne-Manneville S: In vitro assay of
primary astrocyte migration as a tool to study Rho GTPase function
in cell polarization. Methods Enzymol. 406:565–578. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Subramani R, Lopez-Valdez R, Arumugam A,
Nandy S, Boopalan T and Lakshmanaswamy R: Targeting insulin-like
growth factor 1 receptor inhibits pancreatic cancer growth and
metastasis. PLoS One. 9:e970162014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Aigner K, Dampier B, Descovich L, Mikula
M, Sultan A, Schreiber M, Mikulits W, Brabletz T, Strand D, Obrist
P, et al: The transcription factor ZEB1 (deltaEF1) promotes tumour
cell dedifferentiation by repressing master regulators of
epithelial polarity. Oncogene. 26:6979–6988. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hazan RB, Qiao R, Keren R, Badano I and
Suyama K: Cadherin switch in tumor progression. Ann N Y Acad Sci.
1014:155–163. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Baserga R, Peruzzi F and Reiss K: The
IGF-1 receptor in cancer biology. Int J Cancer. 107:873–877. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
King H, Aleksic T, Haluska P and Macaulay
VM: Can we unlock the potential of IGF-1R inhibition in cancer
therapy? Cancer Treat Rev. 40:1096–1105. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yin S, Girnita A, Strömberg T, Khan Z,
Andersson S, Zheng H, Ericsson C, Axelson M, Nistér M, Larsson O,
et al: Targeting the insulin-like growth factor-1 receptor by
picropodophyllin as a treatment option for glioblastoma. Neuro
Oncol. 12:19–27. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim YS, Lee HA, Lim JY and Kim Y, Jung CH,
Yoo SH and Kim Y: β-Carotene inhibits neuroblastoma cell invasion
and metastasis in vitro and in vivo by decreasing level of
hypoxia-inducible factor-1α. J Nutr Biochem. 25:655–664. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hiraoka N, Allen E, Apel IJ, Gyetko MR and
Weiss SJ: Matrix metalloproteinases regulate neovascularization by
acting as pericellular fibrinolysins. Cell. 95:365–377. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lu KW, Chen JC, Lai TY, Yang JS, Weng SW,
Ma YS, Lu PJ, Weng JR, Chueh FS, Wood WG and Chung JG: Gypenosides
inhibits migration and invasion of human oral cancer SAS cells
through the inhibition of matrix metalloproteinase-2 −9 and
urokinase-plasminogen by ERK1/2 and NF-kappa B signaling pathways.
Hum Exp Toxicol. 30:406–415. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Brew K, Dinakarpandian D and Nagase H:
Tissue inhibitors of metalloproteinases, evolution, structure and
function. Biochim Biophys Acta. 1477:267–283. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Thiery JP and Sleeman JP: Complex networks
orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell
Biol. 7:131–142. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Raftopoulou M and Hall A: Cell migration:
Rho GTPases lead the way. Dev Biol. 265:23–32. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Clemmons DR: Modifying IGF1 activity: An
approach to treat endocrine disorders, atherosclerosis and cancer.
Nat Rev Drug Discov. 6:821–833. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wojtalla A, Salm F, Christiansen DG,
Cremona T, Cwiek P, Shalaby T, Gross N, Grotzer MA and Arcaro A:
Novel agents targeting the IGF-1R/PI3K pathway impair cell
proliferation and survival in subsets of medulloblastoma and
neuroblastoma. PLoS One. 7:e471092012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang JY, Del Valle L, Gordon J, Rubini M,
Romano G, Croul S, Peruzzi F, Khalili K and Reiss K: Activation of
the IGF-IR system contributes to malignant growth of human and
mouse medulloblastomas. Oncogene. 20:3857–3868. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yin S, Girnita A, Stromberg T, Khan Z,
Andersson S, Zheng H, Ericsson C, Axelson M, Nistér M, Larsson O,
et al: Targeting the insulin-like growth factor-1 receptor by
picropodophyllin as a treatment option for glioblastoma. Neuro
Oncol. 12:19–27. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cheng CK, Fan QW and Weiss WA: PI3K
signaling in glioma-animal models and therapeutic challenges. Brain
Pathol. 19:112–120. 2009. View Article : Google Scholar : PubMed/NCBI
|
